Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comparing Cytokines, Toxins Adsorbing oXiris Filter to ST150 Filter During CRRT in Patients With Septic Shock
Brief Summary: The Oxiris® filter is a registered product for CRRT already safely used in routine care.

In in vitro experiments, the Oxiris® filter has been demonstrated to adsorb endotoxin and cytokines. Compared to conventional filters this may be advantageous in patients with severe sepsis but neither decreased levels of endotoxin and cytokines nor an improved outcome has been demonstrated with clinical use.

But there are so far little clinical data on the oXiris® filter on humans. The oXiris® filter will be investigated in a double blind randomized crossover setting against a traditional filter (ST150). Either filter will be used for 24 hours after which it will be changed to the opposite filter for another 24 hours.

Arterial blood samples will be drawn at start and then 1, 3, 8, 16 and 24 hours after the start of each filter, and analyzed for endotoxin (EAA assay), TNF-α, IL-1β, IL-6 and IL-10 (ELISA) levels. Standard blood tests will be analyzed simultaneously. Data concerning mode and settings of CRRT, heart rate, blood pressure, medication, data concerning ventilatory support and pathogen will be registered.

Primary endpoint: Levels of endotoxin and cytokines will be compared using Student's paired t-test on AUC values for each 24-hour period.


Options:
A: Arm Label: oXiris; Type: ACTIVE_COMPARATOR; Interventions: Device: oXiris | Arm Label: ST150; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: oXiris; Assigned to Arm(s): oXiris
B: Arm Label: Continuous Venovenous Hemofiltration; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Continuous Venovenous Hemofiltration (CVVH) | Arm Label: Continuous Venovenouos Hemodialysis; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Continuous Venovenous Hemodialysis (CVVHD) | Intervention Type: PROCEDURE; Name: Continuous Venovenous Hemofiltration (CVVH); Assigned to Arm(s): Continuous Venovenous Hemofiltration | Intervention Type: PROCEDURE; Name: Continuous Venovenous Hemodialysis (CVVHD); Assigned to Arm(s): Continuous Venovenouos Hemodialysis
C: Arm Label: heparinized saline priming group; Type: EXPERIMENTAL; Interventions: Drug: heparinized saline priming group | Arm Label: nafamostat infusion group after heparinized saline priming; Type: ACTIVE_COMPARATOR; Interventions: Drug: nafamostat infusion after heparinized saline priming | Intervention Type: DRUG; Name: heparinized saline priming group; Assigned to Arm(s): heparinized saline priming group | Intervention Type: DRUG; Name: nafamostat infusion after heparinized saline priming; Assigned to Arm(s): nafamostat infusion group after heparinized saline priming
D: Arm Label: heparin anticoagulation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Heparin | Arm Label: citrate anticoagulation; Type: EXPERIMENTAL; Interventions: Drug: Citrate | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): heparin anticoagulation | Intervention Type: DRUG; Name: Citrate; Assigned to Arm(s): citrate anticoagulation

Answer: A